Drug intelligence / Profile preview

HRS-2303

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Small Molecules

Overview

HRS-2303 is a small molecule therapeutic candidate currently under development by Tuojie Biotech (拓界生物医药). While specific details regarding its biological target and primary indication have not been publicly disclosed in detail, it is part of the company's internal research pipeline focusing on innovative small molecule drugs. The compound is being advanced through early-stage research and development alongside other candidates in Tuojie Biotech's portfolio, which spans oncology, metabolic diseases, and inflammatory conditions.

Beyond the preview

Go deeper on HRS-2303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-2303.

Explore the full profile